Haematological immune-related adverse events induced by anti-PD-1 or anti-PD-L1 immunotherapy: a descriptive observational study.
Fiche publication
Date publication
janvier 2019
Journal
The Lancet. Haematology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr NARDIN Charlée
Tous les auteurs :
Delanoy N, Michot JM, Comont T, Kramkimel N, Lazarovici J, Dupont R, Champiat S, Chahine C, Robert C, Herbaux C, Besse B, Guillemin A, Mateus C, Pautier P, Saïag P, Madonna E, Maerevoet M, Bout JC, Leduc C, Biscay P, Quere G, Nardin C, Ebbo M, Albigès L, Marret G, Levrat V, Dujon C, Vargaftig J, Laghouati S, Croisille L, Voisin AL, Godeau B, Massard C, Ribrag V, Marabelle A, Michel M, Lambotte O
Lien Pubmed
Résumé
Anti-programmed cell death 1 (PD-1) and anti-programmed cell death ligand 1 (PD-L1) antibodies are novel immunotherapies for cancer that can induce immune-related adverse events (irAEs). These adverse events can involve all organs, including the haemopoietic system. Thus far, haematological irAEs (haem-irAEs) have not been extensively characterised. This study aims to provide a comprehensive report of the haem-irAEs induced by anti-PD-1 or anti-PD-L1.
Mots clés
Aged, Antibodies, Monoclonal, Humanized, adverse effects, Antineoplastic Agents, Immunological, adverse effects, Female, Humans, Immunotherapy, adverse effects, Male, Middle Aged, Programmed Cell Death 1 Receptor, drug effects
Référence
Lancet Haematol. 2019 01;6(1):e48-e57